Distinct miRNA profiles are associated with malignant transformation of pancreatic cystic tumors revealing potential biomarkers for clinical use

References

• D’Angelica M, Brennan MF, Suriawinata AA, Klimstra D, Conlon KC. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann. Surg. 239(3), 400–408 (2004).
   PubMed Web of Science ®Google Scholar
• Shi C, Hruban RH. Intraductal papillary mucinous neoplasm. Hum. Pathol. 43(1), 1–16 (2012).
   PubMed Web of Science ®Google Scholar
• Salvia R, Crippa S, Falconi M et al. Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut 56(8), 1086–1090 (2007).
   PubMed Web of Science ®Google Scholar
• Pang JC, Minter RM, Kwon RS et al. The role of cytology in the preoperative assessment and management of patients with pancreaticobiliary tract neoplasms. J. Gastrointest. Surg. 17(3), 501–510 (2013).
   PubMed Web of Science ®Google Scholar
• Lubezky N, Loewenstein S, Ben-Haim M et al. MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas. Surgery doi:10.1016/j.surg.2012.11.016 (2013) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Mino-Kenudson M, Fernández-del Castillo C, Baba Y et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut 60(12), 1712–1720 (2011).
   PubMed Web of Science ®Google Scholar
• Izeradjene K, Combs C, Best M et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11(3), 229–243 (2007).
   PubMed Web of Science ®Google Scholar
• Pérez-Mancera PA, Guerra C, Barbacid M, Tuveson DA. What we have learned about pancreatic cancer from mouse models. Gastroenterology 142(5), 1079–1092 (2012).
   PubMed Web of Science ®Google Scholar
• Jiao LR, Frampton AE, Jacob J et al. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS ONE 7(2), e32068 (2012).
   Web of Science ®Google Scholar
• Frampton AE, Gall TM, Castellano L, Stebbing J, Jiao LR, Krell J. Towards a clinical use of miRNAs in pancreatic cancer biopsies. Expert Rev. Mol. Diagn. 13(1), 31–34 (2013).
   PubMed Web of Science ®Google Scholar
• Habbe N, Koorstra JB, Mendell JT et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol. Ther. 8(4), 340–346 (2009).
   PubMed Web of Science ®Google Scholar
• Caponi S, Funel N, Frampton AE et al. The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. Ann. Oncol. 24(3), 734–741 (2013).
   PubMed Web of Science ®Google Scholar
• Szafranska AE, Davison TS, John J et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26(30), 4442–4452 (2007).
   PubMed Web of Science ®Google Scholar
• Munding JB, Adai AT, Maghnouj A et al. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Int. J. Cancer 131(2), E86–E95 (2012).
   PubMed Web of Science ®Google Scholar
• Jang JS, Jeon HS, Sun Z et al. Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin. Cancer Res. 18(13), 3658–3667 (2012).
   PubMed Web of Science ®Google Scholar
• Saini S, Yamamura S, Majid S et al. MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res. 71(19), 6208–6219 (2011).
   PubMed Web of Science ®Google Scholar
• Ryu S, McDonnell K, Choi H et al. Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration. Cancer Cell 23(1), 63–76 (2013).
   PubMed Web of Science ®Google Scholar
• Saini S, Majid S, Shahryari V et al. miRNA-708 control of CD44(+) prostate cancer-initiating cells. Cancer Res. 72(14), 3618–3630 (2012).
   PubMed Web of Science ®Google Scholar
• Greither T, Grochola L, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumours associates with poorer survival. Int. J. Cancer 126(1), 73–80 (2009).
   Web of Science ®Google Scholar
• Wellner U, Schubert J, Burk UC et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11(12), 1487–1495 (2009).
   PubMed Web of Science ®Google Scholar
• Kim S, Lee UJ, Kim MN et al. MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J. Biol. Chem. 283(26), 18158–18166 (2008).
   PubMed Web of Science ®Google Scholar
• Hanoun N, Delpu Y, Suriawinata AA et al. The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin. Chem. 56(7), 1107–1118 (2010).
   PubMed Web of Science ®Google Scholar
• Delpu Y, Lulka H, Sicard F et al. The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool. PLoS ONE 8(1), e55513 (2013).
   Google Scholar
• Zhang Y, Fan KJ, Sun Q et al. Functional screening for miRNAs targeting Smad4 identified miR-199a as a negative regulator of TGF-β signalling pathway. Nucleic Acids Res. 40(18), 9286–9297 (2012).
   PubMed Web of Science ®Google Scholar
• Jamieson NB, Morran DC, Morton JP et al. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin. Cancer Res. 18(2), 534–545 (2012).
   PubMed Web of Science ®Google Scholar
• Papaconstantinou IG, Manta A, Gazouli M et al. Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas 42(1), 67–71 (2013).
   PubMed Web of Science ®Google Scholar
• Laurila EM, Sandström S, Rantanen LM et al. Both inhibition and enhanced expression of miR-31 lead to reduced migration and invasion of pancreatic cancer cells. Genes Chromosomes Cancer 51(6), 557–568 (2012).
   PubMed Web of Science ®Google Scholar
• Caponi S, Vasile E, Funel N et al. Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms. Eur. J. Surg. Oncol. 39(4), 396–403 (2013).
   PubMed Web of Science ®Google Scholar